12:00 AM
Oct 05, 2009
 |  BC Week In Review  |  Company News  |  Deals

ORCA Therapeutics, VCN Biosciences deal

ORCA received an exclusive, worldwide license to develop and commercialize VCN's T1 oncolytic adenovirus technology for cancer. VCN will receive an undisclosed...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >